Merck
CN
  • A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature.

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature.

Anticancer research (1996-01-01)
V Barbounis, A Efremidis
ABSTRACT

Castleman's disease is a rare benign condition of uncertain etiology, with several forms. It is postulated that a dysregulated inflammatory response may play a role in the pathogenesis of this disease. We report on a case of Castleman's disease treated with the histamine receptor-2 antagonist cimetidine with favourable response, suggesting that cimetidine may be helpful in the treatment of this disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cimetidine
Supelco
Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
Cimetidine, European Pharmacopoeia (EP) Reference Standard
Cimetidine for peak identification, European Pharmacopoeia (EP) Reference Standard
Cimetidine for system suitability, European Pharmacopoeia (EP) Reference Standard